Hepatic Arterial Infusion Chemotherapy (HAIC)

How it works

Preparation

Risks & contraindications

Comparisons

Background

Highlighted claims

• In NEO-ERA-01, HAIC is performed via percutaneous femoral artery catheterization without an implantable pump. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
• HAIC delivers high local drug concentrations directly to liver tumors while minimizing systemic toxicity. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
• HAIC has been used in locally advanced ICC for more than 20 years. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
• HAIC-related adverse events can include hepatic artery spasm, catheter displacement, arterial dissection, pseudoaneurysm, and thrombosis. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial
• Prospective and retrospective studies show HAIC achieves superior objective response rates compared with systemic chemotherapy in ICC. — Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial